LAVA Therapeutics NV

As of May 17, 2022, LAVA Therapeutics NV is considered a risky investment due to its overvaluation, negative ROE of -128.56%, and poor performance compared to peers and the S&P 500, with a one-year return of -12.5%.

As of May 17, 2022, LAVA Therapeutics NV is considered overvalued and risky, with key ratios indicating challenges in revenue generation and a negative P/E ratio due to losses, despite a strong year-to-date return of 43.01%.

As of May 1, 2025, LAVA Therapeutics NV exhibits a mildly bearish trend, influenced by bearish daily moving averages and weekly RSI, despite some mildly bullish signals from the weekly MACD and KST.

LAVA Therapeutics NV is a micro-cap biotechnology company focused on pharmaceuticals, currently reporting a net profit loss of $3 million and a market cap of $34.20 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -128.56%.

As of Jun 18, LAVA Therapeutics NV has a market capitalization of 34.20 million and reported net sales of 4.99 million with a net profit of -27.95 million over the latest four quarters. The company's shareholder's funds are 27.75 million, with total assets of 80.83 million.